Orgenesis, a developer of advanced cell therapies, manufacturer and service provider, has entered into a Master Service and Joint Venture Agreement with TheraCell Advanced Biotechnology for the clinical development and commercialization of cell and gene therapies. The JV will implement Orgenesis’ point-of-care (POCare) cell therapy strategy with a goal to bring Advanced Therapy Medicinal Products (ATMPs) to patients at the therapeutic setting by leveraging Orgenesis’ and TheraCell’s combined tec...